Vaccines are a matter of national security, a leading global health figure said this week, warning that rising anti-vaccine ...

Richard Hatchett, who leads the Cepi, a partnership of governments and philanthropies that was among the first to fund Covid-19 vaccines, said epidemics and pandemics remained a key global threat ...

Vaccines are a matter of national security, a leading global health figure said this week, warning that rising anti-vaccine ...

The race to have vaccines ready for distribution within three months of the next pandemic breaking out needs to take into account the possibility of an AI being used to artificially create a virus or ...

OSLO, 13 FEB--As deadly disease outbreaks become ever more frequent and disruptive, CEPI (the Coalition for Epidemic Preparedness Innovations) is setting out a bold plan to transform the way the world ...

In an era where biological threats loom larger than ever, from emerging viruses to potential weaponized pathogens, the U.S. military's readiness hinges on innovative partnerships beyond traditional ...

Africa's engagement with global vaccine supply over the past five years has shown that access to vaccines and biologics is shaped less by goodwill or financing alone.Vaccine sovereignty in Africa is ...

Surveillance by the Africa Centers for Disease Control (CDC) and Prevention shows one of the continent’s most severe cholera waves in decades, with more than 300,000 suspected cases and over 7,000 ...

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...

Ethiopia has declared the end of its first Marburg virus outbreak. The country completed the mandatory 42 days with no new confirmed cases. Since November 14, 2025, there were 14 cases, including ...

Check out these inspiring stories of global progress highlighting vaccination campaigns, Britain's shift to clean energy and ...

Researchers found that a MERS vaccine induced a durable immune response in humans for at least two years following booster vaccination. Results of the Phase I trial support ongoing vaccine development ...